Pimavanserin
- Generic Name
- Pimavanserin
- Brand Names
- Nuplazid
- Drug Type
- Small Molecule
- Chemical Formula
- C25H34FN3O2
- CAS Number
- 706779-91-1
- Unique Ingredient Identifier
- JZ963P0DIK
- Background
Pimavanserin is an atypical antipsychotic indicated for the treatment of psychiatric disorders. Although the exact mechanism of action is unknown, it is thought that pimavanserin interacts with the serotonin receptors, particularly the 5-HT and HT receptors. Unlike other atypical antipsychotics, pimavanserin lacks inherent dopaminergic activity. In fact, pim...
- Indication
用于伴随帕金森氏病精神病幻觉和妄想的治疗。
- Associated Conditions
- Delusions, Hallucinations
- Associated Therapies
- -
Acadia sells speedy drug review voucher for $150M
Acadia Pharmaceuticals sold a priority review voucher for $150 million, sharing proceeds with Neuren Pharmaceuticals. The voucher, won in March 2023, speeds up FDA reviews. Acadia plans to use the funds for commercial operations, business development, and research in rare diseases and central nervous systems.
Will Auvelity & Sunosi Fuel Axsome's Growth Amid Stiff Competition?
Axsome Therapeutics' Auvelity, launched in 2022 for MDD, generated $118.4M in H1 2024, up 172.8% YoY. Auvelity is being studied for AD agitation and smoking cessation. Sunosi, acquired from Jazz in 2022, contributed $42.2M in H1 2024, up 35.2% YoY. AXSM's pipeline includes AXS-07 for migraine, AXS-14 for fibromyalgia, and AXS-12 for narcolepsy. Competition from Acadia and Jazz's other drugs poses challenges.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath